Devyser Diagnostics Ab · OMXSTO:DVYSR

Devyser Diagnostics Ab — Q3 2025 Earnings Presentation

24 slides from Devyser Diagnostics Ab's earnings presentation, Nov 5, 2025

1. Slide 1: Devyser Earnings call Q3 2025

   Devyser Earnings call Q3 2025 November 5, 2025

2. Slide 2: Today’s presenters

   Today’s presenters Jan Wahlström Sabina Berlin Theis Kipling CEO CFO CCO

3. Slide 3: Jan Wahlström - New CEO

   Jan Wahlström - New CEO

4. Slide 4: Third quarter financials

   Third quarter financials  Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth 16%  Gross margin 75%  EBIT 1.3 MSEK  Cash position 85 MSEK 4

5. Slide 5: Financials Jan-Sept

   Financials Jan-Sept  Revenue • Sales 179 MSEK (153 MSEK) • Growth 17%  Gross margin 81%  EBIT -8 MSEK  Cash position 85 MSEK 5

6. Slide 6: Turning around towards profitability

   Turning around towards profitability · Re-organization delivers improved profitability · Continued growth,supported by thelaunches of new products · Cost focus and continuous improvement Organization that is better balanced and efficient – without compromising growth

7. Slide 7: Product launches in Q3

   Product launches in Q3 · A lot of our focus has been on the launches we did in June, HLA loss and Genomic blood typing. · Q3 is normally more soft on launches, but today we launched CFTR IVDR · We work on moving products from RUO and IVDD to IVDR

8. Slide 8: More highlights

   More highlights · MolDx feedback · FDA path for Accept

9. Slide 9: Third quarter 2025

   Third quarter 2025

10. Slide 10: Third quarter

    Third quarter  Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth +15.7% 10

11. Slide 11: Rolling 12 months net sales

    Rolling 12 months net sales 11

12. Slide 12: Sales by region

    Sales by region % of Q3 % of Q3 % Growth Q3 2025 Q3 2024 2025 2024 QoQ EMEA 51.7 45.2 91.8% 92.7% 14.4% Asia-Pacific 1.9 2.1 3.4% 4.2% -6.6% North and South 2.7 1.5 4.8% 3.1% 87.0% America Total 56.4 48.7 100.0% 100.0% 15.7% 12

13. Slide 13: Sales by sales channel

    Sales by sales channel % of Q3 % of Q3 % Growth Q3 2025 Q3 2024 2025 2024 QoQ Direct sales 46.4 36.7 82.3% 75.2% 26.5% Distributor sales 10.0 12.1 17.7% 24.8% -17.3% Total 56.4 48.7 100.0% 100.0% 15.8% 13

14. Slide 14: Third quarter

    Third quarter  Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth +15.7%  Gross margin 75.0% (72.3%) 14

15. Slide 15: Third quarter

    Third quarter  Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth +15.7%  Gross margin 75.0% (72.3%)  EBIT • 1.3 MSEK (-21.8) 15

16. Slide 16: Third quarter

    Third quarter  Revenue • Sales 56.4 MSEK (48.7 MSEK) • Growth +15.7%  Gross margin 75.0% (72.3%)  EBIT • 1.3 MSEK (-21.8)  Strong financial position • 84.9 MSEK in liquidity • No debts 16

17. Slide 17: Highlights Q3 and Commercial outlook

    Highlights Q3 and Commercial outlook

18. Slide 18: Q3 commercial recap

    Q3 commercial recap · A good quarter focused on getting HLA Loss and Genomic Blood Typing off the ramp · Lead generation YTD more than 3x doubled vs last year driving a strong growth in number of new customers · ASHI meeting generated a lot of interest in HLA Loss · North America continues to grow w

19. Slide 19: Update on Thermo Fisher Scientific

    Update on Thermo Fisher Scientific  Q3 was slow due to a strong Q2  ASHI conference was solid and we continue to gain traction together with Thermo Fisher  Orders from Thermo Fisher are expected to strenghten in Q4 following the established pattern  FDA program continues on plan

20. Slide 20: North America update

     Devyser Genomic Laboratories  Accept cfDNA feedback from MolDx was received with additional requests which we’re currently assessing  Cyted collaboration is following plan – revenues and volumes to consistently increase following their succesful capital raise North  RHD testing remains being a

21. Slide 21: Europe

    • A quarter higher is Italy that grew 19% during Q3 which is very strong (excluding Chimerism) • Broadly across Europe we see continued upselling progress within existing accounts incl. University of Leuven where we're discussing a significant tender for Europe CFTR NGS as described in one of the an

22. Slide 22: Going forward

    Going forward • Execute on updated strategy – now delivering another positive EBIT quarter • Capitalize on our RnD efforts • Continue to work on organizational efficiency • Continue our path to profitability and positive cash flow 22

23. Slide 23: Q&A

    O&A Dvysr.

24. Slide 24: Thank you!

    Thank you! Connect with us www.devyser.com

Devyser Diagnostics — Q3 2025 Earnings Presentation on 6ix